Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real‐world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2017-06, Vol.92 (6), p.E105-E107 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E107 |
|---|---|
| container_issue | 6 |
| container_start_page | E105 |
| container_title | American journal of hematology |
| container_volume | 92 |
| creator | Michallet, Anne‐Sophie Campidelli, Arnaud Lequeu, Helene Dilhuydy, Marie‐Sarah Tournilhac, Olivier Fornecker, Luc‐Matthieu Dupuis, Jehan Cymbalista, Florence De Guibert, Sophie Delmer, Alain Vilque, Jean‐Pierre Ghez, David Leblond, Veronique Subtil, Fabien Feugier, Pierre Ysebaert, Loic |
| description | |
| doi_str_mv | 10.1002/ajh.24715 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01653723v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1895930649</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4225-2e092afdb399345cc65354d78f65bfe90b942765927b91bdf29beebbf82c9f523</originalsourceid><addsrcrecordid>eNp1kcGO0zAQhi0EYsvCgRdAlrjsHrq1nTiJuVUrui2K1AucIzsZb1zSODhOSzjxCLzf3ngSHFp2T5w8Gn_zeeQfobeU3FBC2ELu6hsWp5Q_QzNKRDLPEs6eoxmJEhpqIi7Qq77fEUJpnJGX6IJlTHBOyQw9bJQbvGmNwqbFB3AjhqYC14y4k95A63t8NL7GDhrZ9VAtHGgnS28DWdbOtqbEzbjvaluOfqph-Ap7Iz_gZZiRze-fv47WNRWG7x24ICwBW41T-uT3gfNQTQusnAzANNv7oRqxdnaPfQ3hIkzWeNO29hDmDoDz80N46-5la36Erm3x1WqTb6_xvbND9xq90LLp4c35vERfVh8_367n-fZuc7vM52XMGJ8zIIJJXalIiCjmZZnwiMdVmumEKw2CKBGzNOGCpUpQVWkmFIBSOmOl0JxFl-j65K1lU3TO7KUbCytNsV7mxdQjNChTFh1oYN-f2M7ZbwP0vtjZwbVhvYJmgouIJLF4MpbO9n348UctJcUUeREiL_5GHth3Z-Og9lA9kv8yDsDiBBxNA-P_TcXy0_qk_AO0Zbml</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1895930649</pqid></control><display><type>article</type><title>Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real‐world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><creator>Michallet, Anne‐Sophie ; Campidelli, Arnaud ; Lequeu, Helene ; Dilhuydy, Marie‐Sarah ; Tournilhac, Olivier ; Fornecker, Luc‐Matthieu ; Dupuis, Jehan ; Cymbalista, Florence ; De Guibert, Sophie ; Delmer, Alain ; Vilque, Jean‐Pierre ; Ghez, David ; Leblond, Veronique ; Subtil, Fabien ; Feugier, Pierre ; Ysebaert, Loic</creator><creatorcontrib>Michallet, Anne‐Sophie ; Campidelli, Arnaud ; Lequeu, Helene ; Dilhuydy, Marie‐Sarah ; Tournilhac, Olivier ; Fornecker, Luc‐Matthieu ; Dupuis, Jehan ; Cymbalista, Florence ; De Guibert, Sophie ; Delmer, Alain ; Vilque, Jean‐Pierre ; Ghez, David ; Leblond, Veronique ; Subtil, Fabien ; Feugier, Pierre ; Ysebaert, Loic</creatorcontrib><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.24715</identifier><identifier>PMID: 28295510</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Cardiovascular Diseases - chemically induced ; Chronic lymphocytic leukemia ; Dose-Response Relationship, Drug ; Female ; France - epidemiology ; Gastrointestinal Diseases - chemically induced ; Geriatrics ; Hematologic Diseases - chemically induced ; Hematology ; Human health and pathology ; Humans ; Infections - etiology ; Inhibitor drugs ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Life Sciences ; Lymphatic leukemia ; Male ; Molecular Targeted Therapy ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Pyrazoles - administration & dosage ; Pyrazoles - adverse effects ; Pyrazoles - therapeutic use ; Pyrimidines - administration & dosage ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Salvage Therapy ; Targeted cancer therapy ; Treatment Outcome</subject><ispartof>American journal of hematology, 2017-06, Vol.92 (6), p.E105-E107</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4225-2e092afdb399345cc65354d78f65bfe90b942765927b91bdf29beebbf82c9f523</citedby><cites>FETCH-LOGICAL-c4225-2e092afdb399345cc65354d78f65bfe90b942765927b91bdf29beebbf82c9f523</cites><orcidid>0000-0002-4256-8126 ; 0000-0001-8478-5623 ; 0000-0001-9324-7958 ; 0000-0003-4102-7261 ; 0000-0002-9438-621X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.24715$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.24715$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,777,781,882,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28295510$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://uca.hal.science/hal-01653723$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Michallet, Anne‐Sophie</creatorcontrib><creatorcontrib>Campidelli, Arnaud</creatorcontrib><creatorcontrib>Lequeu, Helene</creatorcontrib><creatorcontrib>Dilhuydy, Marie‐Sarah</creatorcontrib><creatorcontrib>Tournilhac, Olivier</creatorcontrib><creatorcontrib>Fornecker, Luc‐Matthieu</creatorcontrib><creatorcontrib>Dupuis, Jehan</creatorcontrib><creatorcontrib>Cymbalista, Florence</creatorcontrib><creatorcontrib>De Guibert, Sophie</creatorcontrib><creatorcontrib>Delmer, Alain</creatorcontrib><creatorcontrib>Vilque, Jean‐Pierre</creatorcontrib><creatorcontrib>Ghez, David</creatorcontrib><creatorcontrib>Leblond, Veronique</creatorcontrib><creatorcontrib>Subtil, Fabien</creatorcontrib><creatorcontrib>Feugier, Pierre</creatorcontrib><creatorcontrib>Ysebaert, Loic</creatorcontrib><title>Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real‐world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cardiovascular Diseases - chemically induced</subject><subject>Chronic lymphocytic leukemia</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>France - epidemiology</subject><subject>Gastrointestinal Diseases - chemically induced</subject><subject>Geriatrics</subject><subject>Hematologic Diseases - chemically induced</subject><subject>Hematology</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Infections - etiology</subject><subject>Inhibitor drugs</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Life Sciences</subject><subject>Lymphatic leukemia</subject><subject>Male</subject><subject>Molecular Targeted Therapy</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrazoles - administration & dosage</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Salvage Therapy</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcGO0zAQhi0EYsvCgRdAlrjsHrq1nTiJuVUrui2K1AucIzsZb1zSODhOSzjxCLzf3ngSHFp2T5w8Gn_zeeQfobeU3FBC2ELu6hsWp5Q_QzNKRDLPEs6eoxmJEhpqIi7Qq77fEUJpnJGX6IJlTHBOyQw9bJQbvGmNwqbFB3AjhqYC14y4k95A63t8NL7GDhrZ9VAtHGgnS28DWdbOtqbEzbjvaluOfqph-Ap7Iz_gZZiRze-fv47WNRWG7x24ICwBW41T-uT3gfNQTQusnAzANNv7oRqxdnaPfQ3hIkzWeNO29hDmDoDz80N46-5la36Erm3x1WqTb6_xvbND9xq90LLp4c35vERfVh8_367n-fZuc7vM52XMGJ8zIIJJXalIiCjmZZnwiMdVmumEKw2CKBGzNOGCpUpQVWkmFIBSOmOl0JxFl-j65K1lU3TO7KUbCytNsV7mxdQjNChTFh1oYN-f2M7ZbwP0vtjZwbVhvYJmgouIJLF4MpbO9n348UctJcUUeREiL_5GHth3Z-Og9lA9kv8yDsDiBBxNA-P_TcXy0_qk_AO0Zbml</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Michallet, Anne‐Sophie</creator><creator>Campidelli, Arnaud</creator><creator>Lequeu, Helene</creator><creator>Dilhuydy, Marie‐Sarah</creator><creator>Tournilhac, Olivier</creator><creator>Fornecker, Luc‐Matthieu</creator><creator>Dupuis, Jehan</creator><creator>Cymbalista, Florence</creator><creator>De Guibert, Sophie</creator><creator>Delmer, Alain</creator><creator>Vilque, Jean‐Pierre</creator><creator>Ghez, David</creator><creator>Leblond, Veronique</creator><creator>Subtil, Fabien</creator><creator>Feugier, Pierre</creator><creator>Ysebaert, Loic</creator><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-4256-8126</orcidid><orcidid>https://orcid.org/0000-0001-8478-5623</orcidid><orcidid>https://orcid.org/0000-0001-9324-7958</orcidid><orcidid>https://orcid.org/0000-0003-4102-7261</orcidid><orcidid>https://orcid.org/0000-0002-9438-621X</orcidid></search><sort><creationdate>201706</creationdate><title>Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real‐world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group</title><author>Michallet, Anne‐Sophie ; Campidelli, Arnaud ; Lequeu, Helene ; Dilhuydy, Marie‐Sarah ; Tournilhac, Olivier ; Fornecker, Luc‐Matthieu ; Dupuis, Jehan ; Cymbalista, Florence ; De Guibert, Sophie ; Delmer, Alain ; Vilque, Jean‐Pierre ; Ghez, David ; Leblond, Veronique ; Subtil, Fabien ; Feugier, Pierre ; Ysebaert, Loic</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4225-2e092afdb399345cc65354d78f65bfe90b942765927b91bdf29beebbf82c9f523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cardiovascular Diseases - chemically induced</topic><topic>Chronic lymphocytic leukemia</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>France - epidemiology</topic><topic>Gastrointestinal Diseases - chemically induced</topic><topic>Geriatrics</topic><topic>Hematologic Diseases - chemically induced</topic><topic>Hematology</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Infections - etiology</topic><topic>Inhibitor drugs</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Life Sciences</topic><topic>Lymphatic leukemia</topic><topic>Male</topic><topic>Molecular Targeted Therapy</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrazoles - administration & dosage</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Salvage Therapy</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michallet, Anne‐Sophie</creatorcontrib><creatorcontrib>Campidelli, Arnaud</creatorcontrib><creatorcontrib>Lequeu, Helene</creatorcontrib><creatorcontrib>Dilhuydy, Marie‐Sarah</creatorcontrib><creatorcontrib>Tournilhac, Olivier</creatorcontrib><creatorcontrib>Fornecker, Luc‐Matthieu</creatorcontrib><creatorcontrib>Dupuis, Jehan</creatorcontrib><creatorcontrib>Cymbalista, Florence</creatorcontrib><creatorcontrib>De Guibert, Sophie</creatorcontrib><creatorcontrib>Delmer, Alain</creatorcontrib><creatorcontrib>Vilque, Jean‐Pierre</creatorcontrib><creatorcontrib>Ghez, David</creatorcontrib><creatorcontrib>Leblond, Veronique</creatorcontrib><creatorcontrib>Subtil, Fabien</creatorcontrib><creatorcontrib>Feugier, Pierre</creatorcontrib><creatorcontrib>Ysebaert, Loic</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michallet, Anne‐Sophie</au><au>Campidelli, Arnaud</au><au>Lequeu, Helene</au><au>Dilhuydy, Marie‐Sarah</au><au>Tournilhac, Olivier</au><au>Fornecker, Luc‐Matthieu</au><au>Dupuis, Jehan</au><au>Cymbalista, Florence</au><au>De Guibert, Sophie</au><au>Delmer, Alain</au><au>Vilque, Jean‐Pierre</au><au>Ghez, David</au><au>Leblond, Veronique</au><au>Subtil, Fabien</au><au>Feugier, Pierre</au><au>Ysebaert, Loic</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real‐world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2017-06</date><risdate>2017</risdate><volume>92</volume><issue>6</issue><spage>E105</spage><epage>E107</epage><pages>E105-E107</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28295510</pmid><doi>10.1002/ajh.24715</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-4256-8126</orcidid><orcidid>https://orcid.org/0000-0001-8478-5623</orcidid><orcidid>https://orcid.org/0000-0001-9324-7958</orcidid><orcidid>https://orcid.org/0000-0003-4102-7261</orcidid><orcidid>https://orcid.org/0000-0002-9438-621X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2017-06, Vol.92 (6), p.E105-E107 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01653723v1 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content |
| subjects | Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cardiovascular Diseases - chemically induced Chronic lymphocytic leukemia Dose-Response Relationship, Drug Female France - epidemiology Gastrointestinal Diseases - chemically induced Geriatrics Hematologic Diseases - chemically induced Hematology Human health and pathology Humans Infections - etiology Inhibitor drugs Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Life Sciences Lymphatic leukemia Male Molecular Targeted Therapy Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Salvage Therapy Targeted cancer therapy Treatment Outcome |
| title | Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real‐world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T01%3A05%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibrutinib%20in%20very%20elderly%20patients%20with%20relapsed/refractory%20chronic%20lymphocytic%20leukemia:%20A%20real%E2%80%90world%20experience%20of%2071%20patients%20treated%20in%20France:%20A%20study%20from%20the%20French%20Innovative%20Leukemia%20Organization%20(FILO)%20group&rft.jtitle=American%20journal%20of%20hematology&rft.au=Michallet,%20Anne%E2%80%90Sophie&rft.date=2017-06&rft.volume=92&rft.issue=6&rft.spage=E105&rft.epage=E107&rft.pages=E105-E107&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.24715&rft_dat=%3Cproquest_hal_p%3E1895930649%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1895930649&rft_id=info:pmid/28295510&rfr_iscdi=true |